The COVID-19 pandemic has spread to more than 33 million people worldwide, sending the healthcare industry racing to find a safe and effective vaccine. With over 42 candidates now in human trials, the conversation is evolving from not only when a vaccine(s) will be available, but also how those vaccines will be distributed to effectively halt the spread of the virus. The episode opens with a discussion of the changes to the traditional vaccine development process being undertaken to meet the objectives of Operation Warp Speed and (05:11) the potential long-term impacts it could have on future vaccines. At (07:18), the conversation shifts to a discussion of potential challenges for local health organizations developing and executing COVID-19 vaccine distribution plans – from storage requirements (08:39), to the need for consecutive doses (10:15), to difficulties of reaching underserved patients (10:54). Innovative partnerships (12:00) will be critical in ensuring widespread distribution, the spread of public health information, and ensuring patient compliance (13:00). Capacity planning (13:17) and provider recruitment (13:38) will be critical as demand and scope change from phase to phase of distribution. The conversation closes (14:13) with a discussion of how public health providers, health plans, and other industry players might encourage adoption of future COVID-19 vaccines, the importance of building public trust in the safety of the vaccines being brought to market, spreading information on when and how to receive the vaccine (16:28), and communicating the long-term efforts that will be required to bring the virus under control (18:17). Based on public opinion polls (19:50), there will certainly be a need for public education on (21:03) potential side effects, (21:55) the risk/benefit ratio, and (23:05) the long-term safety protocols in place in order to ensure widespread adoption of a COVID-19 vaccine.
Trending News EU – 16 June 2022
DEI & Clinical Trials – Driving Meaningful Change
Integrating Diversity, Equity, & Inclusion Throughout Clinical Trials
Pharmaceutical companies who choose not to build DEI into their business strategy are missing out on an opportunity to expand the reach of life-changing therapies while isolating large populations of potential consumers. In this insight, Vynamic covers how to integrate DEI within key steps of the clinical trials process to facilitate better outcomes for both patients and pharmaceutical companies alike.
- Life Sciences
Prioritizing Diversity, Equity, & Inclusion Across Research & Development
Vynamic helped a large, global life sciences organization identify multiple opportunities to improve their DEI strategy within their R&D department, including a roadmap that went beyond diversity in hiring and retention, and included DEI principles applied to the "business of life sciences" to not only help advance client priorities, but also raise the bar for the pharmaceutical industry.
- Life Sciences
Trending News – June 2nd, 2022
Activating Diversity, Equity, & Inclusion Through Employee Resource Councils
The leadership of a large home healthcare provider sought to operationalize their Diversity, Equity, & Inclusion (DEI) strategy across their organization. Read how Vynamic helped this organization activate Employee Resource Councils, successfully onboard a DEI leader, and introduce internal DEI branding.
Trending News – May 19, 2022
Innovations Across the Atlantic: What the US & UK Can Learn From Each Other When it Comes to Crisis Care
Unlocking Patient Access Through The Digital Front Door
Patient access is one of the most critical issues plaguing the current healthcare industry. A large, academic medical center and nationally-recognized integrated delivery network sought Vynamic's help to create innovative solutions to enable optimal patient access, opening the door to increasing health equity.
Want to learn more? Get in Touch!
Contact our team to learn more about how we can help your needs.